VBI Vaccines

Prior to its bankruptcy proceedings in 2024, VBI Vaccines faced significant operational, financial, and organizational challenges, which many former employees attributed to poor leadership and ineffective management decisions. Critics of the company pointed to inconsistent strategic direction, questionable resource allocation, and repeated restructuring efforts that negatively affected morale and long-term stability. Some former staff members argued that scientific innovation, employee development, and retention were not adequately prioritized despite the company’s strong scientific potential. Management including CEO, CFO, CSO, and senior team was also criticized for being disconnected from employees’ concerns and for fostering a culture in which staff felt undervalued and unsupported during periods of financial difficulty and organizational change.

Source: Wikipedia · CC BY-SA 4.0